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Précis: Surgical site infections are an ever-increasing phenomenon worldwide due to
different factors. This brief report aimeds to highlight at a glance, for both physicians and
political and institutional leaders, the economic burden of surgical site infections.
Objectives: This brief report aimed to highlight the economic burden of surgical site
infections (SSIs).
Methods: A narrative review focusing on this subject has been carried out.
Results: Surgical site infections are responsible for generating important costs. In 2017,
a French cohort highlighted a mean cost of each SSI treatment to be around e1,814;
the same year, the Centers for Disease Control and Prevention guidelines evaluated the
mean cost caused by SSI treatment to be from $10,443 to $25,546 per SSI. This cost
depends on many factors including the patient himself and the type of surgery.
Conclusions: Prevention of the risk of infection is, therefore, a profitable concept for
surgery that must be integrated within all healthcare managements worldwide.
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HIGHLIGHTS
- Surgical site infections in digestive surgery generate an additional cost ranging from e306 to
e26,815 per infected patient, depending on the depth and the comorbidities of the patient.
- The increased length of stay for digestive surgery-related infections ranges from 4 to 29 days.
- These data, therefore, encourage us to maintain a preventative approach both for the direct
benefit of the patient and for the reduction of healthcare expenditure.
INTRODUCTION
Surgical site infections (SSIs) represent the third most common source of nosocomial infections
in France with an estimated prevalence of 0.83% (0.71–0.95) just after urinary tract and lower
respiratory infections. SSIs have been on the rise, predominantly those affecting deep tissues,
organs, and cavities (1).
Surveillance data shows an SSI rate of 1.97% for digestive surgery [95%
CI = (1.81–2.13)]. The incidence varies depending on the type of intervention.
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Indeed, inguinal or crural hernia operations have an SSI rate of
0.6% [95% CI= (0.37–0.83)], while in colorectal surgery, the rate
is 4.93% (2.91–6.94). In general, the level of SSI is higher than
that found in other surgeries because the surgical field is heavily
colonized by digestive flora (2).
These postoperative infections not only have consequences
for the patient themselves but also have an economic impact
on the healthcare system. It is, therefore, important to estimate
the medico-economic impact of SSIs in general and in digestive
surgery in particular.
Their consequences in terms of morbidity and mortality
are often significant and their surgical or medical management
(antibiotic therapy) is often complex.
Specialized and multidisciplinary structures have been setup
to improve the treatment of these patients during complex
SSIs, such as the reference centers for complex osteoarticular
infections in 2008 in France called “CRIOA” (3, 4). This
multidisciplinary approach is expanding into the management
of other types of healthcare-associated infections due to
changes in medical practice and the antibiotic resistance profile
of bacteria.
The economic challenges for society are substantial and
particularly important in the period of the economic crisis that
we have been going through over the past several years. A recent
report from the Office of the Auditor General considers that
infections associated with healthcare represent globally “a cost
(...) difficult to establish; a previous study places them in a range
of 2.4 billion euros (1 to 6 billion)” (5).
This study aimed to produce a summary of the cost induced
by the occurrence of these SSIs.
METHODOLOGY
A literature review was carried out on PubMed and Syrtis using
the following keywords: “hospital-acquired infection,” “hospital
cost,” “economic impact,” “surgical site infection,” “length of
stay,” “economic consequence,” “economic burden,” and “surgical
wound” between 2009 and 2020.
All countries were included in this study regardless of their
income status.
The following were excluded from this review of the literature:
• Publications in languages other than English or French;
• Articles relating to children due to pediatric specificity;
• Studies from the point of view of the patient; and
• Studies related to costs of society;
Costs described in the studies were borne by patients themselves
or society/healthcare systems. Eligible articles included cost
analysis with partial or complete economic evaluations. The costs
have been converted into euros. They have been standardized
in 2020 by consulting the history of currency rates on the site:
https://fxtop.com/fr/historique-rate-change.php. For the given
year, the currency rate taken is that on December 30, 2020.
When the studies did not relate specifically to digestive
surgery, we individualized the specific costs of this surgery when
the methodology of the studies identified allowed it.
RESULTS
About 21 studies met the inclusion criteria and were, therefore,
analyzed to summarize the cost and the increase in the length of
hospital stay associated with SSIs. The main results are shown in
Table 1 below.
We note that the cost range related to SSIs in digestive surgery
is e306–26,815 vs. e2,610–46,570 for other types of surgery.
Similarly, the increase in the length of stay associated with SSIs
in digestive surgery ranges from 2.8 to 29 days vs. 2.9–54 days for
other types of surgery.
Regarding low- and middle-income countries, five studies
have been found: China (n = 2) (22, 23), Jordan (n = 1) (24),
Brazil (n= 1) (25), and India (n= 1) (26). Additional cost of SSIs
ranged from $3865 (Brazil) to $29,610 (India).
DISCUSSION
This study highlighted that most of the costs of SSIs treatment
(without taking into consideration the cost of initial surgery)
are borne by surgical revision (37.9% of the total cost) and by
the need for rehospitalization (59.4%) (15, 17). However, it is
important to stress out that additional costs to manage SSIs arise
from medical staff and investigations (27).
This analysis made it possible to identify a range of costs
directly induced by the occurrence of an SSI. The variations
observed are sometimes significant and this is explained by:
• Structural reasons linked to the country (and, therefore, to the
healthcare system); but no differences were found regarding
the status of the country by itself (high income vs. low/middle
income) in accordance with the recent study of Monahan
et al. (28). However, it seems important to underline that few
studies have been found for low-/middle-income countries
and that they are as heterogeneous as those in Europe. In
France, since 2018, with the “Surveillance and prevention of
the risk of infection in surgery and interventional medicine”
(SPICMI) mission, the most frequent surgical procedures in
France are followed and their SSIs are recorded. Considering
that this surveillance has the ambition to be fully automatized
within the next few years, the evaluation of costs may be more
efficient and accurate in accordance with the European Centre
for Disease Prevention and Control in the future.
• Methodological aspects: First, with the definition of SSI: most
of the studies use the definition of the Center of Disease
Control (CDC) for SSI but do not apply it; moreover, follow-
up is not setup for some studies missing post-discharge SSIs.
Second, with the analysis: the type of surgery (specific or
mixed), patient population, and cost items including analysis
with or without confounders are very heterogeneous.
Indeed, the comparison of health systems and their financing
does not allow a homogeneous treatment of the data resulting
from these studies. The point of view of the study is also a factor
that can make the analysis complex: the cost will not be the same
if we look from the point of view of society, from the point of view
of the hospital, and from the point of view of the paying agency
or the patient. In the articles reviewed for this study, we excluded
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TABLE 1 | Increase in duration and additional costs associated with surgical site infections (SSIs).
Type of surgery Additional average cost
(euros) /episode [by SSI]
Increase of hospital stay (days)
[sum of days for the
rehospitalization]
Country Reference
All 4,490–24,514 2.9–54 FR, GER, ITA, ES, UK Badia et al. (6)
All 2,857–46,570 4.9–32.2 NL Broex et al. (7)
All 7,262 4.26 USA Boltz et al. (8)
Digestive 7,330 – UK Guest et al. (9)
Digestive 12,703–14,736 8.9–10.0 USA De Lissovoy et al. (10)
Digestive 3,540–26,815 4–29 UK Jenks et al. (11)
Digestive 2,430–3,640 15 FRA Lamarsalle et al. (12)
Digestive 306–2,281 2.8–9.5 JPN Fukuda et al. (13)
Digestive 7,159–9,703 4.6–7.9 USA Keenan et al. (14)
Neurosurgery 8,177–22,344 3–7 USA Patel et al. (15)
Neurosurgery 14,262 6.9–9.6 USA Blumberg et al. (16)
Neurosurgery 9,002 – UK Atkinson et al. (17)
Cardiac 19,661 – UK Chiwera et al. (18)
Cardiac 2,670–28,062 – GER Graf et al. (19)
Cardiac 24693 48–49.7 JPN Kobayashi et al. (20)
Orthopedic 8,581–13,108 5.7–9.2 GER Poultsides et al. (21)
GER, Germany; ITA, Italy; ES, Spain; UK, United Kingdom; NL, Netherlands; US, United States; JPN, Japan.
studies whose point of view was that of the patient or society (not
considering indirect costs).
In addition, some studies have included a wide variety of
surgical procedures, which may reinforce the heterogeneity of
the data in the pooled economic analysis. Thus, we observe
that SSIs occurring after cardiac surgery or neurosurgery have
an overall greater economic impact than SSIs occurring after
cutaneous or gynecological surgery (6, 7, 15). The cost induced
by SSIs in digestive surgery is in a rather high range compared to
other surgeries.
Finally, the bacterial causative agents responsible for SSIs,
regardless of surgery, do not all have the same pathogenicity and,
therefore, the same economic consequences (8).
Patient comorbidities also influence the economic impact of
an SSI (29, 30). However, some studies do not analyze their result
taking into consideration these potential cofounders.
Similarly, the type of SSI is not always specified in the studies.
When we had the information, we could see that the cost of
an SSI is dependent on the depth of the infection. It has been
observed that the deeper the infection, the greater was the
economic consequences.
Thus, in digestive surgery, the cost varies by a factor of
1 (superficial SSI) to 2.3 (organ SSI), and the length of stay
attributable to the SSI of the organ increases by a factor of
3.4 (13). There is a link between the increased length of stay
associated with the infection and the observed additional cost.
This almost linear relationship should be analyzed with the
same limitations as those mentioned above: factors related to the
patients, the depth of the infection, and the type of surgery (8, 10).
As a result, this study shows the challenges toward assessing
with accuracy the costs of SSIs as huge range costs have been
identified between the studies. We have, thus, the main limitation
of the study, which can be explained by different factors such
as differences in follow-up between the studies, non use of the
definition of SSI according to the CDC (implying a minimum of
30 days of follow-up of surgery), the absence of adjustment for
potential confounders in some studies, and heterogeneity within
studies highlighting the lack of robustness of studies.
CONCLUSION
Surgical site infections are responsible for a cost that is very
likely >e1 billion (it is the second most common cause of
nosocomial infection which costs at least e2–4 billion per year
in France). This report has shown that this cost depends on many
factors including the patient himself and the type of surgery: the
more the type of surgery is contaminated, the more the risk of
SSI increases, leading to digestive surgery as one of the type of
surgeries at risk of SSIs.
Beyond the expected benefit for the patient, this report can
and should serve as new arguments for public authorities to
invest in the prevention of SSIs. An old and recent study on the
cost-effectiveness analysis of preventive measures in surgery can
be found in the literature (31–33).
Given the economic resources that are depleted, the
prevention of the risk of infection is, therefore, a profitable
concept for surgery that must be put forward.
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